Preoperative motor mapping by navigated transcranial magnetic brain stimulation improves outcome for motor eloquent lesions

Sandro M. Krieg, Jamil Sabih, Lucia Bulubasova, Thomas Obermueller, Chiara Negwer, Insa Janssen, Ehab Shiban, Bernhard Meyer, and Florian Ringel

Department of Neurosurgery (S.M.K., J.S., L.B., T.O., C.N., I.J., E.S., B.M., F.R.); TUM-Neuroimaging Center, Klinikum rechts der Isar, TU München, Germany (S.M.K., J.S., T.O.)

Corresponding Author: Sandro M. Krieg, MD, Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany (sandro.krieg@lrz.tum.de).

Ethics committee registration number: 2793/10

Background. Navigated transcranial magnetic stimulation (nTMS) has been proven to influence surgical indication and planning. Yet there is still no clear evidence how these additional preoperative functional data influence the clinical course and outcome. Thus, this study aimed to compare patients with motor eloquently located supratentorial lesions investigated with or without preoperative nTMS in terms of clinical outcome parameters.

Methods. A prospectively enrolled cohort of 100 patients with supratentorial lesions located in motor eloquent areas was investigated by preoperative nTMS (2010–2013) and matched with a control of 100 patients who were operated on without nTMS data (2006–2010) by a matched pair analysis.

Results. Patients in the nTMS group showed a significantly lower rate of residual tumor on postoperative MRI (OR 0.3828; 95% CI 0.2062–0.7107). Twelve percent of patients in the nTMS and 1% of patients in the non-nTMS group improved while 75% and 81% of the nTMS and non-nTMS groups, respectively, remained unchanged and 13% and 18% of patients in the nTMS and non-nTMS groups, respectively, deteriorated in postoperative motor function on long-term follow-up (P = .0057). Moreover, the nTMS group showed smaller craniotomies (nTMS 22.4 ± 8.3 cm²; non-nTMS 26.7 ± 11.3 cm²; P = .0023).

Conclusions. This work increases the level of evidence for preoperative motor mapping by nTMS for rolandic lesions in a group comparison study. We therefore strongly advocate nTMS to become increasingly used for these lesions. However, a randomized trial on the comparison with the gold standard of intraoperative mapping seems mandatory.

Keywords: brain tumor, matched pair, preoperative mapping, rolandic region, transcranial magnetic stimulation.
Materials and methods

Patients

Topographic association between tumor and Rolandic cortex and therefore indication for nTMS and intraoperative neuromonitoring (IOM) was assessed by magnetic resonance imaging (MRI) for all patients. Between 2010 and 2013 100 consecutive patients with motor eloquently located supratentorial lesions underwent craniotomy in our department after receiving nTMS motor mapping. Moreover, this prospectively enrolled cohort was matched with a historic control operated on from 2006 to 2010 in our department with the same distribution of tumor types. Matching was performed for tumor location, preoperative paresis, and histology out of a cohort of 218 patients. The characteristics of both groups are outlined in Table 1. Data analysis was performed blinded to the assigned group.

Mean follow-up in terms of clinical evaluation in the outpatient department was 9.4 ± 8.7 months (median 7.1 months, range 0.2–27.2 months) in the nTMS and 16.0 ± 20.9 months (median 6.2 months, range 0.1–79.4 months) in the non-nTMS group.

Clinical assessment

All patients were evaluated for muscle strength, coordination, sensory function, and cranial nerve function according to a standardized protocol that was established 2006 in our department. Clinical assessment was performed blinded to the nTMS data. After surgery, neurological status was routinely assessed after awakening from anesthesia and daily from the first postoperative day until discharge, again at 6–8 weeks postoperatively, and during follow-ups on a regular basis every 3–12 months depending on tumor type. Any new surgery-related paresis was differentiated between permanent and temporary. A new permanent paresis was defined as a new or aggravated paresis due to surgery that did not return to the preoperative status during follow-up. A temporary paresis was defined as a new or aggravated postoperative paresis, which disappeared at least during the regular 8-week follow-up interval. However, every patient who presented with a new paresis directly after anesthesia underwent a postoperative computed tomography (CT) scan to exclude secondary hemorrhage.

Ethical standard

The study is in accordance with ethical standards of the Declaration of Helsinki and was approved by the local institutional review board (registration number: 2793/10). Informed consent was obtained prior to every nTMS examination.

Magnetic resonance imaging

Pre- and postoperative MRI scans were performed on all patients using a 3 Tesla MR scanner in combination with an 8-channel phased array head coil (Achieva 3T, Philips Medical Systems, The Netherlands B.V.) for contrast-enhanced 3D gradient echo sequence, T2 FLAIR, and diffusion tensor imaging (DTI). The contrast-enhanced 3D gradient echo sequence dataset was transferred to the nTMS system (eXimia 3.2 and eXimia 4.3, Nexstim Oy, Helsinki, Finland). Each patient also underwent a MRI scan the day after surgery to evaluate the EOR, including T1 sequences with and without contrast enhancement, T2 FLAIR, and diffusion-weighted imaging (DWI) to detect any postoperative ischemic events. During follow-up, MRI scans were also performed on a regular basis every 3–12 months depending on tumor entity and current oncological therapy. Follow-up MRI scans were reviewed for recurrent tumors because the neurological status during follow-up was only considered during progression-free survival.

For final analysis, all MRI scans performed in our center are evaluated in an imaging meeting including board certified neuroradiologists and neurosurgeons.

For this study, we also analyzed the extent of craniotomy by postoperative MRI or CT scans in all 200 patients in order to achieve the most exact data. Since all craniotomies are performed rectangular (parallel to the sagittal suture) in our department, we measured anterior-posterior (ap) and lateral direction as well as the area of the craniotomy as the product of both values.

Navigated transcranial magnetic stimulation

Transcranial magnetic stimulation (TMS) is used since 1985 to elicit MEP, especially in the neurological diagnostic routine, by inducing an electric field within the motor cortex, which causes neuronal depolarization and therefore an action potential. This action potential is then transmitted to the muscles and can be measured as MEP. In the last years we are now also able to navigate the TMS coil and therefore its site of cortical stimulation. For visualization of the stimulated cortical spots, a 3D gradient echo sequence is used. The applied nTMS systems (eXimia 3.2 and eXimia 4.3, Nexstim Oy, Helsinki, Finland) both used a biphasic figure-8 TMS coil with a 50 mm radius as the magnetic stimulator.

Table 1. Patient data

<table>
<thead>
<tr>
<th></th>
<th>nTMS</th>
<th>non-nTMS</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>age</td>
<td>53.1 ± 15.7</td>
<td>55.5 ± 17.1</td>
<td>.3025</td>
</tr>
<tr>
<td>gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>59%</td>
<td>66%</td>
<td>.3809</td>
</tr>
<tr>
<td>female</td>
<td>41%</td>
<td>34%</td>
<td></td>
</tr>
<tr>
<td>preoperative paresis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>none</td>
<td>66%</td>
<td>73%</td>
<td>.2710</td>
</tr>
<tr>
<td>mild</td>
<td>24%</td>
<td>15%</td>
<td></td>
</tr>
<tr>
<td>severe</td>
<td>10%</td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>astrocytoma II</td>
<td>17%</td>
<td>15%</td>
<td>.9996</td>
</tr>
<tr>
<td>astrocytoma III</td>
<td>12%</td>
<td>14%</td>
<td></td>
</tr>
<tr>
<td>glioblastoma</td>
<td>37%</td>
<td>37%</td>
<td></td>
</tr>
<tr>
<td>metastasis</td>
<td>24%</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>AVM</td>
<td>3%</td>
<td>3%</td>
<td></td>
</tr>
<tr>
<td>cavernoma</td>
<td>3%</td>
<td>3%</td>
<td></td>
</tr>
<tr>
<td>other</td>
<td>4%</td>
<td>4%</td>
<td></td>
</tr>
</tbody>
</table>

Detailed overview on age, gender, preoperative neurological status, and histology of the nTMS compared to the non-nTMS group. Preoperative paresis: none = no paresis, mild = BMRC grade of muscle strength ≥ 4/5, severe = BMRC grade of muscle strength ≤ 3/5, histology: AVM = arteriovenous malformation.
which is attached to an infrared tracking system (Polaris Spectra, Waterloo, Ontario, Canada) as reported earlier.\textsuperscript{5,9} One day prior to surgery, all enrolled patients of the nTMS group underwent primary motor cortex mapping by a protocol described previously by an examiner with high experience in nTMS.\textsuperscript{5,9} Briefly, resting motor threshold (rMT) was determined and mapping was performed using 110% rMT for the upper extremity and 130% for the lower extremity.\textsuperscript{5} The mapping was started at the lateral part of the hand knob and was performed in 3–5 mm steps perpendicular to the sulci until stimulation did not elicit any further MEP in any direction. All cortical spots at which a MEP was evoked were evaluated as positive motor mapping points representing the cortical representation of the mapped muscles.

Positive motor mapping points were then exported from the nTMS system via the DICOM standard.

**nTMS data within intraoperative neuronavigation**

During surgery, neuronavigation was used (Vector Vision 2, Vector Vision Sky, or Curve; BrainLAB AG, Feldkirchen, Germany) in both groups. In the nTMS group, the motor cortex as outlined by nTMS was visualized by the neuronavigation system. To achieve this, the nTMS motor areas were exported as DICOM files by the nTMS system and imported to the neuronavigation planning unit (BrainLAB iPlan\textsuperscript{TM} Net Cranial 3.0.1; BrainLAB AG, Feldkirchen, Germany). The data set of nTMS-positive motor areas was fused to a continuous sagittal image set of a T1-weighted 3D gradient echo sequence as well as T2 FLAIR, and positron emission tomography (PET) if necessary. After fusion the nTMS-positive motor areas were then defined as objects by simple auto segmentation and available as 3D objects within the intraoperative neuronavigation as described earlier.\textsuperscript{10} The additional implementation of nTMS data into the neuronavigation planning took about 2–5 min per patient.

Figure 1 illustrates the visualization of preoperative nTMS mapping data and its intraoperative use by the neuronavigation system.

**Surgical technique**

All 200 lesions were resected by monopolar direct cortical stimulation for monitoring of MEPs as IOM as described in earlier reports.\textsuperscript{11,12} Surgical technique did not vary between groups.

**Statistical analysis**

For testing the distribution of several attributes, a Chi-square or Fisher Exact test was performed. Differences between the 2 groups were tested using the Mann-Whitney-Wilcoxon test for non-parametric and t-test for parametric distribution. All results are presented as mean ± standard deviation (SD) and as odds ratios (OR) with 95% confidence intervals (CI) (GraphPad Prism 5.0c, La Jolla, CA, USA). The level of significance was 0.05 (two-sided) for each statistical test.

**Role of the funding source**

The study was completely financed by institutional grants through the Department of Neurosurgery. The corresponding author has full access to all the data in the study and has final responsibility for the decision to submit for publication.

**Results**

**Preoperative nTMS mapping**

Preoperatively performed motor cortex mapping was performed in all 100 consecutive patients of the nTMS group. There were no patients who were not able to perform nTMS. The mean rMT was 34.5% ± 9.3% maximum stimulator output. All 100 patients were asked about their experience of nTMS: 6 patients described their experience of nTMS mapping as unpleasant, and no patient found it painful.

**Influence on surgery**

**Craniotomy size**

Cranietomy extension in the ap direction for nTMS was 4.9 ± 0.9 cm (median 5.0 cm, range 3.0–7.6 cm) and 5.4 ± 1.5 cm (median 5.0 cm, range 1.0–10.6 cm) for non-TMS patients (P = .0023; Fig. 2A). Lateral cranietomy extension was 4.5 ± 1.1 cm (median 4.0 cm, range 3.0–9.0 cm) for the nTMS and 4.8 ± 1.1 cm (median 4.0 cm, range 1.0–8.0 cm) for the non-TMS group (P = .0471; Fig. 2B). Overall size of the bone flap was 22.4 ± 8.3 cm\(^2\) (median 20.0 cm\(^2\), range 9.0–54.0 cm\(^2\)) for the nTMS and 26.7 ± 11.3 cm\(^2\) (median 25.0 cm\(^2\), range 4.0–64.0 cm\(^2\)) for the non-TMS group (P = .0023; Fig. 2C).

**Duration of surgery**

Duration of surgery was 196.2 ± 57.5 min (median 196.0 min, range 67.0–403.0 min) for nTMS and 189.4 ± 59.8 min (median 177.5 min, range 72.0–410.0 min) for non-nTMS patients (P = .4134).

**General motor outcome**

Sixteen patients (16%) in the nTMS group and 15 patients (15%) in the non-nTMS group suffered from a new surgery-related transient paresis with no statistically significant difference (OR 1.079; CI 0.5016–2.323). Moreover, 13 patients (13%) in the nTMS group and 18 patients (18%) in the non-nTMS group suffered from a new permanent paresis on long-term follow-up (OR 0.6807; CI 0.5016–2.323). Moreover, 13 patients (13%) in the nTMS group and 18 patients (18%) in the non-nTMS group suffered from a new permanent paresis on long-term follow-up (OR 0.6807; CI 0.5016–2.323).

When also including neurological improvement in the analysis, 12 patients (12%) in the nTMS group and 1 patient (1%) in the non-nTMS group improved while 75 patients (75%) in the nTMS group and 81 patients (81%) in the non-nTMS group remained unchanged and 13 patients (13%) in the nTMS group and 18 patients (18%) in the non-nTMS group presented with decreased postoperative motor function on long-term follow-up (P = .0057; Fig. 3).

**Permanent surgery-related deficit depending on preoperative paresis**

Regarding the rate of preoperative pareses and their effect on outcome, we found 34 patients (34%) with preoperative paresis in the nTMS and 27 patients (27%) in the non-nTMS group. On long-term
follow-up, 4 patients (11.8%) in the nTMS group with preoperative paresis deteriorated, compared to 9 patients (13.6%) without preoperative paresis. Eighteen patients (52.9%) with pareses and 57 patients (86.4%) without paresis remained unchanged and 12 patients (35.3%) with preoperative paresis showed improved motor function on long-term follow-up (\(P = .0001\)).

Concerning long-term follow-up of the non-nTMS group, there was no significant correlation between preoperative and new paresis. Two patients (7.4%) with preoperative paresis deteriorated, compared to 16 patients (21.9%) without preoperative paresis.

Twenty-four patients (88.9%) with and 57 patients (78.1%) without paresis remained unchanged and 1 patient (3.7%) with preoperative paresis showed improved motor function on long-term follow-up (\(P = .0709\); Fig. 4).

**Permanent surgery-related deficit depending on tumor type or location**

Tumor type was not associated with a higher rate of permanently new paresis per se (\(P = .2199\)). At both groups, there was also no
significant relationship in either the nTMS (P = .0509) or in the non-nTMS group (P = .1747; Fig. 5). Tumor location, even within the precentral gyrus, was not associated with a higher rate of permanently new paresis in the nTMS (P = .9237) and non-TMS group (P = .7022; Fig. 6).

The nTMS group showed a significantly lower rate of residual tumor. Twenty-two patients (22%) in the nTMS group and 42 patients (42.4%) in the non-nTMS group had residual tumor tissue on postoperative MRI scans (OR 0.3828; CI 0.2062–0.7107). Unexpected residual was observed in 9 patients (9%) in the nTMS group and 32 patients (32.3%) in the non-nTMS group on postoperative MRI scans (OR 0.2071; CI 0.09265–0.4628). However, concerning EOR and its relation to surgery-related permanent paresis, there was no significant difference in either groups (nTMS: OR 1.035; CI 0.2052–5.221; non-nTMS: OR 2.143; CI 0.4966–9.246; Table 2).

Discussion

In neurosurgery it is very difficult to provide a sufficient degree of evidence for technical advances. Besides studies on 5-aminolevulinic acid, DCS, and intraoperative MRI, this is another study actually providing evidence for the usefulness of a new technique in surgical neurooncology.13–15

Preoperative identification of motor areas by nTMS was reported to be helpful in surgical planning for motor eloquent tumors.5,16 Nonetheless, clear data on the actual influence of nTMS motor mapping on the clinical outcome were not available up to now. Thus, this study was performed to increase the level of evidence for this new technique, which might have a severe impact on neurosurgery in the future.

Surgery-related pareses

The central finding of the present study is that nTMS actually lowers the risk for surgery-related paresis (P = .0057; Fig. 3). Yet, mean follow-up was different in both groups due to the earlier date of surgery in the non-nTMS group. However, follow-up of the nTMS group is still long enough to exclude further motor recovery and finally define these pareses as permanent. Thus, this difference does not bias our results.

Apart from the study of Duffau et al. on the impact of IOM for glioma resection, this is only the second study proving that an additional neurophysiological technique reduces deficit rates in patients with motor eloquent lesions.14

The comparably high rate of new surgery-related pareses in both groups must be attributed to the strict rules of our data analysis. Even slight changes in motor function were evaluated as surgery-related pareses.

Craniotomy

Navigated TMS might reduce the required size of craniotomy most likely due to the absent necessity to perform extensive intraoperative mapping when the motor cortex is already outlined on the neuronavigation. Thus, the surgeon can just confirm nTMS data by circumscribed DCS mapping but does not have to do a large craniotomy exposing the whole brain area where the surgeon suspects the motor cortex to be.5

However, when regarding the small mean difference of both groups it might not be clinically relevant, but when regarding the range of both groups, a difference is 3 cm and the difference for the overall size is 10 cm². Thus, this difference might only be relevant in selected cases.

Residual tumor

The nTMS group showed a significantly lower rate of residual tumor on postoperative MRI and therefore a higher rate of gross total resection (GTR). This is somehow surprising as we considered the
continuous visualization of the motor eloquent cortex on the neuronavigation system to cause a more defensive resection and therefore at least comparable resection rates. On the other hand, this visualization is also able to increase the surgeons’ confidence in the anatomy therefore causing more radical resection as also reported by IOM investigations. Duffau et al. not only reported an increased extent of resection but also a lower surgery-related morbidity, which is highly comparable to our results. With regard...
to EOR, we observed a generally high rate of subtotal resection (STR), which can also be attributed to the firm rules of our data analysis. Every suspected residuum was evaluated as STR.

**Tumor location**

In terms of tumor location, we were not able to show any significant difference in surgery-related pareses within each group. However, we observed that nTMS patients suffered from fewer pareses when frontal or parietal lesions were resected (Fig. 6).

**Further mapping techniques**

Other methods of non-invasive cortical motor mapping are MEG and fMRI. Compared MEG, fMRI is broadly available. Some studies were able to show a rather good correlation of fMRI and DCS by showing that fMRI was able to identify the correct gyrus at least. However, fMRI does not measure electrophysiological function but increased metabolism as surrogate parameter of neurological activation. Yet, metabolism can change due to ischemia, edema, or tumor infiltration independently of brain function. Therefore, various studies proved that fMRI lacks sufficient sensitivity and specificity to identify eloquent brain function in the vicinity of intracerebral lesions; therefore, it should not be used for surgical planning. MEG was actually shown to correlate with nTMS, yet, due to the high costs, its

| Table 2. Extent of resection and surgery-related new permanent paresis |
|--------------------------|--------------------------|
|                         | nTMS                     | non-nTMS                  |
|                         | STR | GTR | STR | GTR |
| New permanent paresis   | 13.3% | 12.9% | 27.3% | 16.7% |
| No new permanent paresis | 86.7% | 87.1% | 63.7% | 83.3% |

Detailed overview on the percentage of patients with and without new permanent paresis divided into patients receiving subtotal (STR) or gross total resection (GTR) for both the nTMS and non-nTMS groups.

<table>
<thead>
<tr>
<th>Table 3. Prior nTMS studies on brain tumor patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
</tr>
<tr>
<td>Krings et al., 1997</td>
</tr>
<tr>
<td>Macdonell et al., 1999</td>
</tr>
<tr>
<td>Picht et al., 2009</td>
</tr>
<tr>
<td>Kettelhert et al., 2010</td>
</tr>
<tr>
<td>Picht et al., 2011</td>
</tr>
<tr>
<td>Forster et al., 2011</td>
</tr>
<tr>
<td>Krieg et al., 2012</td>
</tr>
<tr>
<td>Frey et al., 2012</td>
</tr>
<tr>
<td>Krieg et al., 2012</td>
</tr>
<tr>
<td>Paiva et al., 2012</td>
</tr>
<tr>
<td>Tarapore et al., 2012</td>
</tr>
<tr>
<td>Picht et al., 2012</td>
</tr>
<tr>
<td>Krieg et al., 2013</td>
</tr>
<tr>
<td>Sollmann et al., 2013</td>
</tr>
<tr>
<td>Picht et al., 2013</td>
</tr>
</tbody>
</table>

This table provides a condensed overview of previous studies, which are strongly related to the topic of our current study.
distribution and availability are very limited despite its valuable characteristics as a non-invasive mapping technique. In contrast, nTMS with comparably easy and cheap availability represents a remarkable option for non-invasive mapping because it is also based on MEPs via neuronal activation and therefore has a close relationship to DCS, which is widely used by neurosurgeons. Nevertheless, brain shift does not impair the practical use of nTMS: data is mainly used to get an initial impression of the anatomic correlations between function and tumor prior to surgery or at least prior to craniotomy. Moreover, implementation of nTMS into the neuronavigation has its second main value by identifying the precentral gyrus directly after durotomy, which can then be identified visually for the remaining time of surgery. Thus, in our experience, brain shift does not interfere severely with the intraoperative applicability of nTMS data.

Limitations of nTMS
The precision of motor mapping by nTMS can be impaired by various confounding factors, such as the definition of rMT, registration errors, navigation errors, and brain shift after durotomy. Nevertheless, brain shift does not impair the practical use of nTMS: data is mainly used to get an initial impression of the anatomic correlations between function and tumor prior to surgery or at least prior to craniotomy. Moreover, implementation of nTMS into the neuronavigation has its second main value by identifying the precentral gyrus directly after durotomy, which can then be identified visually for the remaining time of surgery. Thus, in our experience, brain shift does not interfere severely with the intraoperative applicability of nTMS data.

Future impact of nTMS on neurosurgery
Preoperative nTMS mapping allows us to inform each patient individually of possible transient postoperative paresis, as we know exactly how close the rolandic region is to the intended resection border in every single case. Thus, we are able to assess operative risks for permanent paresis more precisely and we can use these data to prepare the patient preoperatively. Hence, nTMS data have also influence that cannot be measured by simple outcome studies but may lead to better prepared patients and thus improve patients’ satisfaction. Nonetheless, clinical patient outcome is the most essential parameter in evaluating the worth of a new technique.

Research in context
Systematic review
Literature review was performed on medline by searching for all neurosurgical applications of nTMS. Data was weighted according to the type of trial. Yet, no study design other than simple cohort studies was observed (Table 3). Data on changes in surgical indication were recently published and show that the functional nTMS data have a considerable influence on indication and surgical planning. Due to the design, this study did not investigate the changes in indication for surgery, which will be another key application of nTMS in the future in order to detect potential tumor-induced plastic reshaping of the motor cortex as already described.

Interpretation
This work increases the level of evidence for preoperative motor mapping by nTMS for rolandic lesions in a group comparison study. In order to increase generalisability of the results, all 100 consecutive patients were enrolled into the analysis without focusing on one specific subgroup of lesions.

Future impact of nTMS on neurosurgery
Preoperative nTMS mapping allows us to inform each patient individually of possible transient postoperative paresis, as we know exactly how close the rolandic region is to the intended resection border in every single case. Thus, we are able to assess operative risks for permanent paresis more precisely and we can use these data to prepare the patient preoperatively. Hence, nTMS data have also influence that cannot be measured by simple outcome studies but may lead to better prepared patients and thus improve patients’ satisfaction. Nonetheless, clinical patient outcome is the most essential parameter in evaluating the worth of a new technique.

In order to increase generalisability of the results, all 100 consecutive patients were enrolled into the analysis without focusing on one specific subgroup of lesions.

Therefore, this work greatly improves the level of evidence for this new modality and we strongly advocate nTMS to become increasingly used for these lesions. Yet, a randomized trial on the comparison with the gold standard of intraoperative mapping seems mandatory to gain level I evidence for this modality. Nonetheless, we have to keep in mind that we even do not have level I evidence for intraoperative mapping by DCS although it is seen as standard of care in most countries. Up to now, the best available level of evidence for DCS is also provided by a matched pair analysis with a historic control group.

Funding
The study was completely financed by institutional grants through the Department of Neurosurgery.

Conflicts of interest statement. None declared.

References
12. Krieg SM, Schaffner M, Shiban E, et al. Reliability of intraoperative neurophysiological monitoring using motor evoked potentials...


